DUSP1 and B-cell chronic lymphocytic leukemia: This phenomenon was also observed after DUSP1/6 inhibition in CLL (166), which supports an important role of DUSP1/6-mediated negative regulation of MAPK signaling in CLL cells survival and proposes DUSP1/6 inhibition along with subsequent over-active MAPK signaling as a potential new CLL therapy approach.